Torrent Pharma

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Shares of Torrent Pharmaceuticals rose up to 2.43 per cent to hit an intraday high of Rs 3,180.05 a piece on the BSE

Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, on Wednesday trimmed a 2.9 per cent stake in the company for Rs 3,086 crore through open market transactions. According to the bulk deal data available with the BSE, Torrent Investments Pvt Ltd sold a total of 99.44 lakh shares or 2.94 per cent stake in Torrent Pharmaceuticals. The shares were sold in the price range of Rs 3,103.07-3,104.40 apiece, taking the combined transaction value to Rs 3,086.37 crore. After the stake sale, the combined holding of promoters of Torrent Pharmaceuticals has come down to 68.31 per cent from 71.25 per cent. Details of the buyers of Torrent Pharmaceuticals' shares could not be ascertained on the BSE. Last week, Torrent Pharmaceuticals reported its consolidated profit after tax rose 17 per cent to Rs 453 crore in the September quarter, led by robust sales in the domestic market. The drug firm had reported a profit after tax (PAT) of Rs 386 crore in the July-September period of the l

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent

Stocks to watch today: With Accenture raising its revenue guidance for FY25 to 3-6 per cent, exceeding its previous guidance, IT stocks in India would be in focus today.

In the past one year, Torrent Pharma has outperformed the market by zooming 94 per cent as compared to 27 per cent rise in the BSE Sensex

Deliberations about the stake purchase are ongoing and no final decisions have been made, the people said. Other bidders may still remain interested in acquiring the stake, the people said

Shares of Torrent Pharma slumped up to 4.26 per cent at Rs 646.70 per share on the BSE in Tuesday's intraday deals. This came despite the Indian drugmaker delivering a strong April-June quarter

Revenues in the USA market, however, were down by 12 per cent at Rs 259 crore, falling from Rs 293 crore reported in Q1 FY24

The fall came after the United States Food and Drug Administration (USFDA) issued a Form 483 with five observations for the Indrad unit

Diversified Torrent Group crossed USD 20 billion (Rs 1.68 lakh crore) in market capitalisation on Friday, nearly doubling the market value on the back of robust growth across businesses spanning from pharma to energy. Torrent Group had an m-cap of USD 10.8 billion (Rs 90,230 crore) on June 6, 2023. On Friday, two listed companies of the group, Torrent Pharmaceuticals Limited and Torrent Power Limited gained 2.22 per cent and 2.59 per cent, respectively, setting a new milestone for the group's market capitalisation at USD 20.2 billion at the close of market hours, according to stock exchange data. Shares of the group's flagship Torrent Pharmaceuticals ended at Rs 2,838 each and its arm Torrent Power closed at Rs 1,492.35 apiece on the NSE. Steady growth in the group's market capitalisation mirrors robust financial performance, sustained growth trajectory and business expansions across verticals. At the core of its growth strategy is the business model driven by acquisitions. The g

Stocks to watch on May 27: Divi's Labs net profit soared by an impressive 67.6 per cent year-on-year (YoY), reaching Rs 538 crore compared to Rs 321 crore

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation and amortisation (Ebitda) increased by 21 per cent to Rs 883 crore

Torrent Pharmaceuticals Ltd on Friday reported a 56.45 per cent jump in consolidated net profit to Rs 449 crore in the March quarter, riding on higher revenue. The company had posted a consolidated net profit of Rs 287 crore in the same period of the previous fiscal, Torrent Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations in the fourth quarter of FY24 stood at Rs 2,745 crore as against Rs 2,491 crore in the year-ago period, it added. India revenue was at Rs 1,380 crore, up 10 per cent while the same for Brazil was at Rs 372 crore, registering a growth of 17 per cent, and Germany was at Rs 280 crore, up 11 per cent in the quarter, the company said. On the other hand, US business revenue was at Rs 262 crore, down 6 per cent, it added. Total expenses in the quarter under review was higher at Rs 2,145 crore as compared to Rs 2,067 crore in the same period a year ago. Torrent Pharma said its board has recommended a final dividend of Rs 6 per equity sh

As of May 13, 2024, India's weight in the MSCI Emerging Market Index stood at around 18 per cent, a considerable rise from approximately 8 per cent in early 2020

Pharmaceuticals-to-energy Torrent Group's Mehta family has pledged to donate Rs 5,000 crore over the next five years to the philanthropic foundation set up in name of the group's founder U N Mehta as part of his birth centenary celebrations, the group said on Sunday. Torrent Group celebrated the birth centenary of its founder late Uttambhai Nathalal Mehta (January 14, 1924 to March 31, 1998). The Mehta family has committed to donate Rs 5,000 crore over the next five years to the UNM Foundation to honour the legacy of the visionary philanthropist, the group said in a statement. The Rs 5,000 crore Mehta family committed to donate to the UNM Foundation over the next five years starting April 1, 2024 "will be over and above the statutory CSR contributions of the Torrent Group companies", the statement said. "U N Mehta, the founder of Torrent Group, is remembered for his strong resolve in the face of adversities, business acumen, principled life and humanitarian philanthropy. His early

Torrent Pharmaceuticals Ltd on Tuesday said the US health regulator has issued Form 483 with five procedural observations after inspecting its oral manufacturing facility situated at Bileshwarpura in Gujarat. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The USFDA conducted a pre-approval Inspection at the company's oral manufacturing facility situated in Bileshwarpura, Gujarat from December 5 to 11, 2023, Torrent Pharma said in a regulatory filing. "At the end of the inspection, the company was issued a Form 483 with five procedural observations. There was no observation related to data integrity reported,"it added. The company also said, "we will respond to the USFDA within the prescribed time frame and will work in close collaboration with the agency to ...

Torrent Pharmaceuticals on Friday said it has inked a licensing agreement with Zydus Lifesciences to co-market a product for the treatment of non-alcoholic steato hepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). As per the agreement, the companies will co-market Saroglitazar Mg in the country. Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name Vorxar, Torrent said in a statement. Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones, it noted. As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders. Currently, there is no approved drug for the treatment of NASH and NAFLD anywhere else in the ..

Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD